# Early Breast Cancer: Introduction, Clinical Features, and Treatments

NCOLOGY

VV-MED-118075 © 2022 Lilly USA, LLC. All rights reserved.

### **Breast Cancer: Introduction**

- Breast cancer is the most commonly diagnosed cancer among women worldwide<sup>1</sup>
- Among women, breast cancer accounts for one quarter of cancer cases and ~15% of all cancer deaths worldwide<sup>1</sup>
- Women are at a ~100-fold greater risk
  of developing breast cancer than men<sup>2</sup>
- Early breast cancer, or EBC, is defined as disease confined within the breast and/or neighboring lymph nodes<sup>3</sup>
- Almost 90% of people with breast cancer are diagnosed with EBC<sup>4</sup>

Sung H et al. CA Cancer J Clin 2021;71(3):209-249; 2. <u>https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html</u>; 3. <u>https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html</u>;





EBC=early breast cancer.

breast-cancer; 4. Howlader N et al. J Natl Cancer Inst 2014;106(5):dju055

### **Breast Cancer: Risk Factors**









#### Genetic and hereditary factors

BRCA1/2 mutations, family or personal history of breast or ovarian cancer<sup>1</sup>

### Lifestyle factors

Obesity after menopause, alcohol consumption, and lack of physical activity<sup>2</sup>

#### **Hormone levels**

Increased or abnormal estrogen and progesterone levels; postmenopausal replacement therapy<sup>3,4</sup>

#### Age at menstruation/ childbirth

An early menarche or late menopause, giving birth at old age, and having fewer children<sup>5</sup>

### Mammographic screening rates vary across geographical regions with developed countries reporting higher rates of screening<sup>6</sup>



## **Early Breast Cancer Staging**

Stage 0 IA IB IIA Early-stage IIB IIIA advanced Locally IIIB IIIC

Early breast cancer (EBC) can fall into the following stages according to the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis (TNM) system<sup>1,2</sup>

#### Early-stage

- **Stage 0**: Noninvasive *in situ* carcinoma found inside the ducts (Tis, N0, M0)<sup>1,2</sup>
- Stage IA: Invasive breast cancer <2 cm in size, and have not spread to nearby lymph nodes (T1, N0, M0)<sup>1,2</sup>
- Stage IB: Invasive breast cancer that has grown outside the ducts or lobules, ≤2 cm in size, that may have spread to nearby lymph nodes (T0/T1, N1mi, M0)<sup>1,2</sup>
- Stage IIA: Invasive breast cancer that ≤2 cm in size with spreading to <4 lymph nodes, or ≤5 cm in size without spreading (T0/T1, N1, M0; or T2, N0, M0)<sup>1,2</sup>
- Stage IIB: Invasive breast cancer that is 2-5 cm in size with spreading to <4 lymph nodes or >5 cm in size without spreading (T2, N1, M0; or T3, N0, M0)<sup>1,2</sup>

#### Locally advanced


- Stage IIIA: Locally advanced breast cancer of any size without spread to chest wall or skin with spread to 4-9 nearby lymph nodes, or tumor more than 5 cm in size with spread to 1-3 nearby lymph nodes (T0/1/2/3, N2, M0; or T3, N1, M0)<sup>1,2</sup>
- Stage IIIB: Locally advanced breast cancer with spread to chest wall or skin of breast and <9 axillary lymph nodes (T4, N0/1/2, M0)</li>
- Stage IIIC: Locally advanced breast cancer spread to ≥10 axillary lymph nodes or lymph nodes near the collarbone or breastbone (T0/1/2/3/4, N3, M0)<sup>1,2</sup>



1. Hortobagyi G, et al. AJCC Cancer Staging Manual, Eighth Edition. 2017. 2. https://www.breastcancer.org/symptoms/diagnosis/staging

### **Early Breast Cancer Subtypes**


- Approximately 70% of EBCs are characterized as hormone receptor (HR) positive (estrogen receptor [ER] and/or progesterone receptor [PR]) and human epidermal growth factor 2 (HER2) negative<sup>1</sup>
- Other subtypes include<sup>1</sup>
  - HR positive, HER2 positive
  - HR negative, HER2 positive
  - HR negative, HER2 negative (triple-negative)





### **Early Breast Cancer Subtypes**

- About 80% of patients with EBC are disease-free in the long term<sup>1</sup>
- However, approximately 20% will experience disease recurrence within 10 years<sup>1</sup> and may progress to incurable metastatic disease<sup>2</sup>






### Early Breast Cancer Prognosis

Risk of recurrence by tumor stage<sup>1</sup>

- The risk of recurrence is highest in the first two years following diagnosis<sup>1</sup>
- Critically, patients with disease recurrence have a worse prognosis and poorer overall outcomes<sup>2-4</sup>




From Cheng et al., 2012.<sup>1</sup>



1. Cheng L et al. Cancer Epidemiol Biomark Prev 2012;21(5):800-809; 2. EBCTCG. Lancet 2015;386(10001):1341-1352; 3. Johnston SRD et al. J Clin Oncol 2020;38(34):3987-3998 4. Gerber B et al. Dtsch Arztebl Int 2010;107(6):85-91.

### **Early Breast Cancer Recurrence**

- There are three types of breast cancer recurrence<sup>1</sup>
  - Local: Recurrence within the breast where the cancer originally started. Can also be in the skin and underlying tissues of the chest wall
  - Regional: Recurrence within the lymphatics
    near the affected breast
  - Distant: Recurrence in other parts of the body
- Most common sites are bone, liver, lungs, and brain<sup>1</sup>
- Once distant recurrence has occurred, the disease remains largely incurable, but treatable<sup>2</sup>






1. Gerber B et al. Dtsch Arztebl Int 2010;107(6):85-89; 2. Cardoso F et al. Ann Oncol 2020;31(12):1623-1649.

### **Clinical Features of Early Breast Cancer Recurrence**

- The portion of patients that experience recurrence or distant metastases in EBC is more likely to present high-risk clinical and/or pathologic features<sup>1</sup>
- These features may include:
  - Tumor stage (III)<sup>2</sup>
  - Tumor grade (>3)<sup>3</sup>
  - Tumor size (≥5 cm)<sup>3</sup>
  - Lymph node positivity (≥4 positive lymph nodes)<sup>4</sup>
  - Higher proliferation rates (Ki-67 "high" or ≥20%)<sup>5</sup>
  - Tumor morphology (ductal vs. lobular)<sup>6,7</sup>
  - Positive margins<sup>8</sup>



#### EBC=early breast cancer.


1. Stuart-Harris R et al. Breast (Online) 2019;44:153-159; 2. Cheng L et al. Cancer Epidemiol Biomark Prev 2012;21(5):800-809; 3. Holleczek B et al. BMC Cancer 2019;19(1):520; 4.Pan H et al. N Engl J Med 2017;377(19):1836-1846; 5. Fasching PA et al. Breast Cancer Res Treat 2019;175(3):617-625; 6. Barroso-Sousa R et al. Ther Adv Med Oncol 2016;8(4):261-266; 7. Wasif N et al. Ann Surg Oncol 2010;17(7):1862-1869; 8. Freedman G et al. Int J Radiat Oncol Biol Phys 1999;44(5):1005-1015.



### **Early Breast Cancer Treatments**



- The goal of treatment in HR+, HER2- EBC is to eradicate the cancer and prevent disease recurrence<sup>1</sup>
- The standard of care for HR+, HER2- EBC includes both locoregional therapies and systemic therapies<sup>1</sup>



EBC=early breast cancer; HER2=human epidermal growth factor 2; HR=hormone receptor.

1. NCCN clinical practice guidelines in oncology: breast cancer V.5.2021. <u>https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419</u>.

VV-MED-118075 © 2022 Lilly USA, LLC. All rights reserved.



### **Summary: Early Breast Cancer**

- Early breast cancer (EBC) is a disease confined within the breast and/or neighboring lymph nodes
- Nearly 90% of patients with breast cancer are diagnosed with EBC, of whom approximately 70% have cancers that are HR+, HER2-
- EBC is usually curable with about 80% of patients being disease free long-term. However, up to 20% of patients may experience disease recurrence
- The risk of recurrence is highest in the first two years following diagnosis
- Once distant recurrence has occurred, the disease remains largely incurable, but treatable
- A portion of patients that experience recurrence or distant metastases are more likely to present with high-risk clinicopathological features, such as high levels of Ki-67





EBC=early breast cancer; HER2=human epidermal growth receptor factor 2; HR=hormone receptor.